Canaccord Genuity Group Reaffirms “Buy” Rating for Diaceutics (LON:DXRX)

Diaceutics (LON:DXRX)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity Group in a research note issued on Tuesday, Marketbeat.com reports. They currently have a GBX 160 ($2.01) target price on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 32.78% from the company’s current price.

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($2.01) price objective on shares of Diaceutics in a research report on Tuesday.

Diaceutics Stock Down 2.8 %

DXRX opened at GBX 120.50 ($1.51) on Tuesday. The company has a market capitalization of £101.79 million, a PE ratio of -4,016.67 and a beta of 0.58. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92. Diaceutics has a fifty-two week low of GBX 84.50 ($1.06) and a fifty-two week high of GBX 136 ($1.71). The business has a 50-day moving average of GBX 121.99 and a 200-day moving average of GBX 126.21.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.